Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Preston Bratcher

TitleAffiliate - NJH
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PEDS

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kotas ME, Moore CM, Gurrola JG, Pletcher SD, Goldberg AN, Alvarez R, Yamato S, Bratcher PE, Shaughnessy CA, Zeitlin PL, Zhang IH, Li Y, Montgomery MT, Lee K, Cope EK, Locksley RM, Seibold MA, Gordon ED. IL-13-programmed airway tuft cells produce PGE2, which promotes CFTR-dependent mucociliary function. JCI Insight. 2022 07 08; 7(13). PMID: 35608904.
      View in: PubMed
    2. Shaughnessy CA, Zeitlin PL, Bratcher PE. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. J Cyst Fibros. 2022 Jul; 21(4):637-643. PMID: 35248469.
      View in: PubMed
    3. Shaughnessy CA, Yadav S, Bratcher PE, Zeitlin PL. Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway. Am J Physiol Lung Cell Mol Physiol. 2022 03 01; 322(3):L305-L314. PMID: 35020527.
      View in: PubMed
    4. Nick HJ, Zeitlin PL, Yadav S, Bratcher PE. Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure. Sci Rep. 2021 11 19; 11(1):22616. PMID: 34799640.
      View in: PubMed
    5. Bratcher PE, Zeitlin PL. Expanding CFTR Modulator Testing to Carriers of CFTR Variants. Ann Am Thorac Soc. 2021 11; 18(11):1776-1779. PMID: 34133262.
      View in: PubMed
    6. Shaughnessy CA, Zeitlin PL, Bratcher PE. Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep. 2021 Oct 25; 11(1):21295. PMID: 34697341.
      View in: PubMed
    7. Shaughnessy CA, Zeitlin PL, Bratcher PE. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep. 2021 10 06; 11(1):19810. PMID: 34615919.
      View in: PubMed
    8. Yadav S, Shaughnessy CA, Zeitlin PL, Bratcher PE. Downregulation of epithelial sodium channel (ENaC) activity in human airway epithelia after low temperature incubation. BMJ Open Respir Res. 2021 02; 8(1). PMID: 33622672.
      View in: PubMed
    9. Bratcher PE, Yadav S, Shaughnessy CA, Thornell IM, Zeitlin PL. Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings. Physiol Rep. 2020 10; 8(19):e14603. PMID: 33038073.
      View in: PubMed
    10. Goldfarbmuren KC, Jackson ND, Sajuthi SP, Dyjack N, Li KS, Rios CL, Plender EG, Montgomery MT, Everman JL, Bratcher PE, Vladar EK, Seibold MA. Dissecting the cellular specificity of smoking effects and reconstructing lineages in the human airway epithelium. Nat Commun. 2020 05 19; 11(1):2485. PMID: 32427931.
      View in: PubMed
    11. Nick HJ, Rioux JS, Veress LA, Bratcher PE, Bloomquist LA, Anantharam P, Croutch CR, Tuttle RS, Peters E, Sosna W, White CW. Alleviation of methyl isocyanate-induced airway obstruction and mortality by tissue plasminogen activator. Ann N Y Acad Sci. 2020 11; 1479(1):134-147. PMID: 32233099.
      View in: PubMed
    12. Day BJ, Bratcher PE, Chandler JD, Kilgore MB, Min E, LiPuma JJ, Hondal RJ, Nichols DP. The thiocyanate analog selenocyanate is a more potent antimicrobial pro-drug that also is selectively detoxified by the host. Free Radic Biol Med. 2020 01; 146:324-332. PMID: 31740228.
      View in: PubMed
    13. Roda MA, Xu X, Abdalla TH, Sadik M, Szul T, Bratcher PE, Viera L, Solomon GM, Wells JM, McNicholas CM, Redegeld FA, Folkerts G, Blalock JE, Gaggar A. Proline-Glycine-Proline Peptides Are Critical in the Development of Smoke-induced Emphysema. Am J Respir Cell Mol Biol. 2019 11; 61(5):560-566. PMID: 30958968.
      View in: PubMed
    14. Genschmer KR, Russell DW, Lal C, Szul T, Bratcher PE, Noerager BD, Abdul Roda M, Xu X, Rezonzew G, Viera L, Dobosh BS, Margaroli C, Abdalla TH, King RW, McNicholas CM, Wells JM, Dransfield MT, Tirouvanziam R, Gaggar A, Blalock JE. Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung. Cell. 2019 01 10; 176(1-2):113-126.e15. PMID: 30633902.
      View in: PubMed
    15. Pohl K, Nichols DP, Taylor-Cousar JL, Saavedra MT, Strand MJ, Nick JA, Bratcher PE. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. PLoS One. 2018; 13(12):e0209026. PMID: 30540818.
      View in: PubMed
    16. Bratcher PE, Malcolm KC. Neutrophils and Bacterial Coinfection: Aiding and Abetting. Am J Respir Cell Mol Biol. 2018 12; 59(6):668-669. PMID: 30130423.
      View in: PubMed
    17. Bratcher PE, Hunt KC, Pickard K, Taylor-Cousar JL. Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A. J Cyst Fibros. 2019 03; 18(2):e9-e10. PMID: 30348612.
      View in: PubMed
    18. Xu X, Abdalla T, Bratcher PE, Jackson PL, Sabbatini G, Wells JM, Lou XY, Quinn R, Blalock JE, Clancy JP, Gaggar A. Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur Respir J. 2017 04; 49(4). PMID: 28381428.
      View in: PubMed
    19. Matsye P, Zheng L, Si Y, Kim S, Luo W, Crossman DK, Bratcher PE, King PH. HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases. Glia. 2017 06; 65(6):945-963. PMID: 28300326.
      View in: PubMed
    20. Nichols DP, Happoldt CL, Bratcher PE, Caceres SM, Chmiel JF, Malcolm KC, Saavedra MT, Saiman L, Taylor-Cousar JL, Nick JA. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros. 2017 May; 16(3):358-366. PMID: 28025037.
      View in: PubMed
    21. Szul T, Bratcher PE, Fraser KB, Kong M, Tirouvanziam R, Ingersoll S, Sztul E, Rangarajan S, Blalock JE, Xu X, Gaggar A. Toll-Like Receptor 4 Engagement Mediates Prolyl Endopeptidase Release from Airway Epithelia via Exosomes. Am J Respir Cell Mol Biol. 2016 Mar; 54(3):359-69. PMID: 26222144.
      View in: PubMed
    22. Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, Harris WT, Tirouvanziam R, Gaggar A. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor. J Cyst Fibros. 2016 Jan; 15(1):67-73. PMID: 25769931.
      View in: PubMed
    23. Hahn CS, Scott DW, Xu X, Roda MA, Payne GA, Wells JM, Viera L, Winstead CJ, Bratcher P, Sparidans RW, Redegeld FA, Jackson PL, Folkerts G, Blalock JE, Patel RP, Gaggar A. The matrikine N-a-PGP couples extracellular matrix fragmentation to endothelial permeability. Sci Adv. 2015; 1(3). PMID: 26229981.
      View in: PubMed
    24. Bratcher PE, Gaggar A. Factors influencing the measurement of plasma/serum surfactant protein D levels by ELISA. PLoS One. 2014; 9(11):e111466. PMID: 25365324.
      View in: PubMed
    25. Bratcher PE, Gaggar A. Characterization and prevention of the adsorption of surfactant protein D to polypropylene. PLoS One. 2013; 8(9):e73467. PMID: 24039953.
      View in: PubMed
    26. Bratcher PE, Weathington NM, Nick HJ, Jackson PL, Snelgrove RJ, Gaggar A. MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro. PLoS One. 2012; 7(7):e41881. PMID: 22860023.
      View in: PubMed
    27. Bratcher PE, Nahm MH. Cross-reactivity of current serogroup 6 factor sera from Statens Serum Institut with the recently described pneumococcal serotype 6d. J Clin Microbiol. 2010 Aug; 48(8):3044-5. PMID: 20573866.
      View in: PubMed
    28. Bratcher PE, Kim KH, Kang JH, Hong JY, Nahm MH. Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. Microbiology (Reading). 2010 Feb; 156(Pt 2):555-560. PMID: 19942663.
      View in: PubMed
    29. Rotman E, Bratcher P, Kuzminov A. Reduced lipopolysaccharide phosphorylation in Escherichia coli lowers the elevated ori/ter ratio in seqA mutants. Mol Microbiol. 2009 Jun; 72(5):1273-92. PMID: 19432803.
      View in: PubMed
    30. Bratcher PE, Park IH, Hollingshead SK, Nahm MH. Production of a unique pneumococcal capsule serotype belonging to serogroup 6. Microbiology (Reading). 2009 Feb; 155(Pt 2):576-583. PMID: 19202106.
      View in: PubMed
    Bratcher's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)